- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Sullivan Discusses Role of Dabrafenib Plus Trametinib in Melanoma
November 23rd 2019, 3:47am
Ryan J. Sullivan, MD, discusses the significance of the BRAF/MEK combination dabrafenib and trametinib, which was the first BRAF/MEK inhibitor regimen to be approved by the FDA for the treatment of patients with BRAF V600E–positive stage III melanoma following complete resection.
Targeted Combos Improve OS in Melanoma, But Mitigating Toxicities Essential
November 23rd 2019, 2:51am
Adil Daud, MD, discusses the role of dabrafenib plus trametinib in patients with advanced melanoma and highlighted other combinations under investigation.
Frontline Nivolumab/Ipilimumab Combo Delivers Long-Term OS Advantage in Melanoma
November 23rd 2019, 1:13am
The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) showed a sustained survival benefit compared with nivolumab or ipilimumab alone, according to 5-year follow-up results.
Dr. Danuser Discusses Impact of RacP29S Mutation in Melanoma
November 22nd 2019, 8:10am
Gaudenz Danuser, PhD, discusses how the activation of RacP29S impacts the treatment of patients with melanoma. His lab has been studying the Rac molecule for around 20 years. The RacP29S mutation most commonly appears in melanoma, but it has since been discovered in a few other cancer types as well.
Combination BRAF/MEK Inhibition Induces Potent Antitumor Activity in NRAS+ Melanoma
November 22nd 2019, 3:28am
Combining a BRAF inhibitor with a MEK inhibitor causes endoplasmic reticulum stress in BRAF wild-type, NRAS-mutated melanoma cells, resulting in significant antitumor activity.
Dr. Penson on Treatment Selection in Metastatic Hormone-Sensitive Prostate Cancer
November 22nd 2019, 3:11am
State of the Science Summit on Genitourinary Cancers
David F. Penson, MD, MPH, MMHC, discusses treatment selection in patients with metastatic hormone-sensitive prostate cancer.
Dr. Warner Discusses Findings from COMBI-i Trial in Melanoma
November 22nd 2019, 12:37am
Allison Betof Warner, MD, PhD, discusses the excitement surrounding the findings from the COMBI-i trial that was presented at the 2019 ASCO Annual Meeting. This trial investigated the combination of PD-1 inhibitor spartalizumab with dabrafenib plus trametinib in patients with advanced BRAF V6000mutant melanoma.
Dr. Shoushtari on the Data from the First-in-Human Trial for Tebentafusp in Advanced Melanoma
November 22nd 2019, 12:21am
Alexander N. Shoushtari, MD, discusses the significance of the findings from the first-in-human trial evaluating tebentafusp, a TCR–CD3 bispecific, in patients with advanced melanoma.
Dr. Chang on the Use of PARP Inhibitors in Prostate Cancer
November 20th 2019, 12:55am
State of the Science Summit on Genitourinary Cancers
Sam S. Chang, MD, MBA, discusses the shift toward personalized therapy in prostate cancer.
Selecting Among AR-Directed Agents in Nonmetastatic CRPC
November 16th 2019, 2:51am
State of the Science Summit on Genitourinary Cancers
David Morris, MD, FACS, provides an update on the 3 newest agents available for nonmetastatic castration-resistant prostate cancer treatment and discussed factors to consider when choosing among them.
Dr. Owonikoko on Standard of Care for SCLC
November 15th 2019, 1:08am
PER® New York Lung Cancer Symposium
Taofeek K. Owonikoko, MD, PhD, discusses current standard of care treatments for patients with small cell lung cancer.
Dr. Kelly on Determining Second-Line TKI in Lung Cancer
November 14th 2019, 10:19pm
PER® New York Lung Cancer Symposium
Karen Kelly, MD, discusses how to determine treatment after patients with lung cancer progress on TKIs.
NGS Testing Is Essential Before Induction in NSCLC
November 12th 2019, 3:18am
PER® New York Lung Cancer Symposium
Suresh S. Ramalingam, MD, FASCO, highlights current and emerging therapies for 6 key actionable driver mutations in non–small cell lung cancer.
Dr. Borghaei on the Search for Biomarkers in Lung Cancer
November 12th 2019, 3:01am
PER® New York Lung Cancer Symposium
Hossein Borghaei, DO, MS, discusses the search for biomarkers in lung cancer.
Dr. Halmos on Actionable Biomarkers in NSCLC
November 12th 2019, 2:52am
PER® New York Lung Cancer Symposium
Balazs Halmos, MD, MS, discusses actionable biomarkers in patients with oncogene-driven non–small cell lung cancer.
Dr. Hirsch on the Expansion of Molecular Testing in Lung Cancer
November 12th 2019, 2:45am
PER® New York Lung Cancer Symposium
Fred R. Hirsch, MD, PhD, discusses the expansion of molecular testing in lung cancer.
Plasma NGS Demonstrating Practice-Changing Potential in NSCLC
November 12th 2019, 2:14am
PER® New York Lung Cancer Symposium
Plasma genotyping is the next big thing in non–small cell lung cancer, and it's already impacting clinical practice.
Osimertinib Positioned as Preferred Frontline Treatment for EGFR-Mutant NSCLC
November 12th 2019, 12:10am
PER® New York Lung Cancer Symposium
Zofia Piotrowska, MD, MHS, discusses the role of osimertinib in treating patients with EGFR-mutant non–small cell lung cancer and how it compares with other therapeutic options in that space.
Dr. Ramalingam on FLAURA Trial Results in EGFR-Mutant NSCLC
November 10th 2019, 5:29am
PER® New York Lung Cancer Symposium
Suresh S. Ramalingam, MD, FASCO, discusses updated data from the FLAURA trial in EGFR-mutant non–small cell lung cancer.
Dr. Hanna on Challenges With Consolidation Immunotherapy in Lung Cancer
November 10th 2019, 5:25am
PER® New York Lung Cancer Symposium
Nasser H. Hanna, MD, discusses challenges in consolation immunotherapy for patients with lung cancer.